IVIG does not have one price. The cost of an intravenous immunoglobulin course depends on the product, the patient's body weight, the dose in milligrams per kilogram, the number of infusion visits, the site of care, and the terms of the health plan. Prime Infusions does not publish an IVIG price, because a single figure that ignored those variables would be wrong for almost every patient who read it.
What can be stated precisely is what moves the number, and how to get your own figure in writing. Coverage and out-of-pocket cost are determined by your health plan; Prime Infusions verifies benefits and submits authorization requests. The therapy is described on our IVIG treatment page.
Why is there no single price for IVIG?
IVIG is dosed by body weight, so the grams infused, and therefore the drug cost, scale with the patient, and there are two distinct dosing levels. The Gamunex-C prescribing information specifies replacement dosing of 300 mg/kg to 600 mg/kg every 3 to 4 weeks, and the Privigen prescribing information carries the widest labeled range at 200 mg/kg to 800 mg/kg. Immunomodulatory dosing is several times larger: the 2021 EAN/PNS guideline on chronic inflammatory demyelinating polyneuropathy (CIDP) states that the usual total IVIg dose is 2 g/kg, divided over 2 to 5 days. The number of visits per course differs too, so two patients who both receive IVIG can be several-fold apart on grams and on visits billed.
| Variable | Replacement dosing | Immunomodulatory dosing |
|---|---|---|
| Labeled dose | 300 to 600 mg/kg every 3 to 4 weeks, up to 800 mg/kg on Privigen, Bivigam, Asceniv and Gammaplex 5% | 2 g/kg per course for chronic immune thrombocytopenia and CIDP loading; CIDP maintenance 1 g/kg every 3 weeks |
| Grams for a 70 kg adult (arithmetic, not a label statement) | about 21 to 42 grams | about 70 to 140 grams |
| Visits per course | one visit every 3 to 4 weeks | divided over 2 to 5 consecutive days |
Does the site of care change what IVIG costs?
Site of care is the largest structural lever, and for commercial plans it is a coverage decision, not only a price difference. UnitedHealthcare's commercial site-of-care policy for provider-administered drugs, effective August 1, 2026, names IVIG and subcutaneous immune globulin (SCIG) explicitly and states that alternative sites of care, such as non-hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion services, are well accepted places of service for medication infusion therapy. That policy approves hospital outpatient infusion only on one of seven enumerated criteria: medical instability requiring specialized equipment; physical or cognitive impairment making another site unsafe; severe vascular access issues requiring ultrasound guidance; previous severe adverse events unresponsive to standard interventions; an initial or re-initiated infusion after a 6-month gap; no suitable home, physician office or ambulatory option; and, for IVIG and SCIG only, IgA deficiency with anti-IgA antibodies. Ongoing hospital outpatient approval is capped at 6 months before reassessment.
Where IVIG is administered may therefore need to be approved, not simply chosen. Prime Infusions operates ambulatory infusion centers across New York, including the Manhattan infusion center on the Upper East Side, the Great Neck infusion center in Nassau County, and the Brooklyn infusion center on Foster Avenue. Which sites a plan approves for IVIG is determined by that plan.
Does Medicare cover IVIG under Part B or Part D?
Medicare Part B covers drugs that are not usually self-administered by the patient, under Social Security Act section 1861(t)(1). CMS Transmittal R1800B3 instructs contractors to apply a majority-of-the-time test, asking whether a drug is self-administered more than 50 percent of the time for each indication, then taking a weighted average across indications; absent contrary evidence, intravenous drugs are presumed not self-administered and subcutaneous drugs are presumed self-administered. That presumption is why IVIG given in an infusion center is normally a Part B medical benefit, billed on a J-code to the A/B Medicare Administrative Contractor, while subcutaneous immune globulin taken at home commonly falls to Part D. Part B and Part D carry different deductibles and cost-sharing structures, so the routing changes the bill. Which benefit applies to your product and setting is a Medicare and plan determination. Our comparison of intravenous and subcutaneous immunoglobulin sets out the clinical differences.
What does the Medicare home IVIG benefit actually cover?
The Medicare home IVIG benefit is narrower than most patients expect: it covers primary immunodeficiency disease only. Social Security Act section 1861(zz) covers intravenous immune globulin in the home when the patient has a diagnosed primary immune deficiency disease and the treating practitioner determines home administration is medically appropriate. Section 4134 of the Consolidated Appropriations Act, 2023 made that coverage permanent effective January 1, 2024, replacing the time-limited Medicare IVIG Demonstration.
The benefit pays a single per-visit amount for home IVIG items and services under HCPCS code Q2052, billed to the DME Medicare Administrative Contractor and separate from payment for the drug. The 2026 Q2052 fee schedule amount published by Noridian is $442.19 per visit. Under 42 CFR 414.1700(a), Medicare pays 80 percent of the lesser of the actual charge or the fee schedule amount, so coinsurance remains. Two limits are easy to miss: the benefit does not extend to CIDP, immune thrombocytopenia, multifocal motor neuropathy or dermatomyositis, and CMS states that a hospital, critical access hospital or skilled nursing facility is not an eligible institutional home setting.
What actually determines my out-of-pocket cost for IVIG?
Once product, dose and site of care are fixed, benefit design decides the bill. The variables are:
- Plan type: commercial coverage, Medicare Part B, Medicare Advantage, Medicaid, or a primary plan with secondary coverage.
- Where you stand against the annual deductible when the IVIG course begins.
- Whether cost sharing is percentage coinsurance, which tracks the dose, or a flat copay, which does not.
- Whether the site of care and the administering clinicians are in network.
- Whether the IVIG drug is billed by the infusion center or by a specialty pharmacy, which sets the benefit it runs through.
- The annual out-of-pocket maximum, which for a multi-month IVIG course is often the figure that matters most.
Who bills for the IVIG drug, the infusion center or a specialty pharmacy?
Two distribution models exist, and which one a plan requires changes cost sharing and who issues the bill. The National Infusion Center Association defines white bagging as an arrangement in which a patient purchases a drug from a specialty pharmacy and the specialty pharmacy ships the drug to a provider office, hospital or clinic for administration; under buy-and-bill, infusion centers manage their own drug inventory and bill for drugs administered to patients. White bagging typically routes the IVIG drug through the pharmacy benefit, while buy-and-bill puts it on the medical benefit. Ask which model applies before the first infusion. New York has not changed this by statute: New York Senate Bill S5314 (2025), which would prohibit brown bagging and regulate white bagging, was still in the Senate Insurance Committee as of January 7, 2026 and is not enacted.
Is there copay or financial assistance for IVIG?
Manufacturer copay support programs and independent charitable foundation funds do exist for immune globulin therapy. What cannot be stated reliably is which one a patient qualifies for: eligibility rules, income thresholds, benefit caps, disease-fund open and closed status and funding all change during the year, and many manufacturer copay programs exclude patients with Medicare, Medicaid or other government coverage. Prime Infusions therefore names no specific program here. Ask your prescriber's office and the Prime Infusions team to check what is open for your product, diagnosis and insurance type, and recheck each plan year. Assistance addresses your share of the cost, not whether the plan authorizes the therapy; our article on IVIG prior authorization in New York describes what plans require.
How do I find out what IVIG will actually cost me?
A real number requires five pieces of information, in this order.
- Get the product name, the dose in mg/kg or g/kg, the frequency and the number of visits in the planned course from the prescriber. Without grams and visit count, nobody can price anything.
- Ask the health plan for the benefit determination in writing, naming the product, the HCPCS or J-code, the diagnosis code and the units requested. A verbal call-center quote is not a determination.
- Confirm that the intended site of care is approved for IVIG under that plan.
- Ask whether the IVIG drug will be billed by the infusion center or by a specialty pharmacy, and which benefit each portion falls under.
- Ask for your remaining deductible, your annual out-of-pocket maximum and when the plan year resets. For a multi-month course, that ceiling is often the practical answer.
How do I get benefits verified for IVIG at Prime Infusions?
Prime Infusions verifies benefits and pursues prior authorization for IVIG, then reports back what the plan has determined. Coverage, authorization requirements, site-of-care restrictions and out-of-pocket cost are determined solely by your health plan. To begin, submit the IVIG request form or call Prime Infusions at 718-443-4000. Referring physicians can send a patient through the referrals page, and clinical detail on the therapy is on the Prime Infusions IVIG page.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. IVIG products carry an FDA boxed warning for thrombosis and for renal dysfunction and acute renal failure; review the full prescribing information for the product prescribed to you and discuss your individual risk factors with your treating clinician. Coverage and out-of-pocket cost are determined by your health plan.